Anthracycline cardiotoxicity in transgenic mice overexpressing SR Ca2+ -ATPase

Biochemical and Biophysical Research Communications

Volumn 303, Issue 2, 2003, Pages 504-507

  Burke, Briant E ^a,b   Olson, Richard D ^a,b,c,d   Cusack, Barry J ^b,c,d   Gambliel, Herve A ^b,c   Dillmann, Wolfgang H ^e  

^a Center for Biomedical Research Inc   (United States)

^b MSTI/MSMRI Research Institute   (United States)

^c Boise VA Medical Center   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF SAN DIEGO   (United States)

Author keywords

Anthracycline; Ca ATPase; Cardiotoxicity; Mouse; Sarcoplasmic reticulum; SERCA; Transgenic

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); ANTHRACYCLINE; DOXORUBICIN; ISOENZYME; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CARDIOTOXICITY; CONTROLLED STUDY; FEMALE; HEART; HEART PROTECTION; HISTOLOGY; HYPOTHESIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SARCOPLASMIC RETICULUM; SURVIVAL; TRANSGENIC MOUSE;

MUS MUSCULUS;

EID: 0037418726     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-291X(03)00275-4     Document Type: Article

References (32)

1. Shan K., Lincoff M., Young J.B. Anthracycline-induced cardiotoxicity. Ann. Intern. Med. 125:1996;47-58.
2. Doroshow J. Anthracyclines and anthracenediones. Chabner B.A., Longo D.L. Cancer Chemotherapy and Biotherapy. second ed. 1996;409-434 Lippincott-Raven, Philadelphia.
3. Horenstein M.S., Vander Heide R.S., L'Ecuyer T.J. Molecular basis of anthracycline-induced cardiotoxicity and its prevention. Mol. Genet. Metab. 71:2000;436-444.
4. Olson R.D., Mushlin P.S. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J. 4:1990;3076-3086.
5. Shadle S.E., Bammel B.P., Cusack B.J., Knighton R.A., Olson S.J., Mushlin P.S., Olson R.D. Daunorubicin cardiotoxicity: evidence for the importance of the quinone moiety in a free-radical-independent mechanism. Biochem. Pharmacol. 15:2000;1435-1444.
6. Dodd D.A., Atkinson J.B., Olson R.D., Buck S., Cusack B.J., Fleischer S., Boucek R.J. Jr. Doxorubicin cardiomyopathy is associated with decrease in calcium release channel of the sarcoplasmic reticulum in a chronic rabbit model. J. Clin. Invest. 91:1993;1697-1705.
7. Olson R.D., Li X., Palade P., Shadle S.E., Mushlin P.S., Gambliel H.A., Fill M., Boucek R.J. Jr., Cusack B.J. Sarcoplasmic reticulum calcium release is stimulated and inhibited by daunorubicin and daunorubicinol. Toxicol. Appl. Pharmacol. 169:2000;168-176.
8. Burke B.E., Gambliel H., Olson R.D., Bauer F.K., Cusack B.J. Prevention by dexrazoxane of down-regulation of ryanodine receptor gene expression in anthracycline cardiomyopathy in the rat. Br. J. Pharmacol. 131:2000;1-4.
9. Hagane K., Akera T., Berlin J.R. Doxorubicin: mechanism of cardiodepressant actions in guinea pigs. J. Pharmacol. Exp. Ther. 246:1988;655-661.
10. Wang G.X., Wang Y.X., Zhou X.B., Korth M. Effects of doxorubicinol on excitation-contraction coupling in guinea pig ventricular myocytes. Eur. J. Pharmacol. 423:2001;99-107.
11. Boucek R.J. Jr., Buck S.H., Scott F., Oquist N.L., Fleischer S., Olson R.D. Anthracycline-induced tension in permeabilized cardiac fibers: evidence for the activation of the calcium release channel of sarcoplasmic reticulum. J. Mol. Cell. Cardiol. 25:1993;249-259.
12. Boucek R.J. Jr., Dodd D.A., Atkinson J.B., Oquist N., Olson R.D. Contractile failure in chronic doxorubicin-induced cardiomyopathy. J. Mol. Cell. Cardiol. 29:1997;2631-2640.
13. Arai M., Tomaru K., Takizawa T., Sekiguchi K., Yokayama T., Suzuki T., Nagai R. Sarcoplasmic reticulum genes are selectively down-regulated in cardiomyopathy produced by doxorubicin in rabbits. J. Mol. Cell. Cardiol. 30:1998;243-254.
14. Arai M., Yoguchi A., Takizawa T., Yokauama T., Kanda T., Kurabayashi M., Nagai R. Mechanism of doxorubicin-induced inhibition of sarcoplasmic reticulum Ca-ATPase gene transcription. Circ. Res. 86:1999;8-14.
15. Gambliel H.A., Burke B.E., Cusack B.J., Walsh G.M., Zhang Y.L., Mushlin P.S., Olson R.D. Doxorubicin and C-13 deoxydoxorubicin effects on ryanodine receptor gene expression. Biochem. Biophys. Res. Commun. 2002.
16. Boucek R.J. Jr., Miracle A., Anderson M., Engelman R., Atkinson J., Dodd D.A. Persistent effects of doxorubicin on cardiac gene expression. J. Mol. Cell. Cardiol. 31:1999;1435-1446.
17. Hasenfuss G., Meyer M., Schillinger W., Preuss M., Pieske B., Just H. Calcium handling proteins in the failing human heart. Basic Res. Cardiol. 92(Suppl. 1):1997;87-93. (Review).
18. Zarain-Herzberg A., MacLennan D.H., Periasamy M. Characterization of rabbit sarco(endo)plasmic reticulum Ca-ATPase gene. J. Biol. Chem. 265:1990;4577-4670.
19. Dillmann W.H. Calcium regulatory proteins and their alteration by transgenic approaches. Am. J. Cardiol. 83:1999;89H-91H.
20. 2+ ATPase and decreasing phospholamban expression J. Mol. Cell. Cardiol. 26:1994;1145-1154.
21. He H., Giordano F.J., Hilal-Dandan R., Choi D.J., Rockman W.A., McDonough P.M., Bluhm W.F., Meyer M., Sayen M.R., Swansen E., Dillmann W.H. Overexpression of the rat sarcoplasmic reticulum Ca ATPase gene in the heart of transgenic mice accelerates calcium transients and cardiac relaxation. J. Clin. Invest. 100:1997;380-389.
22. Herman E.H., Ferrans V.J. Timing of treatment of ICRF-187 and its effect on chronic doxorubicin cardiotoxicity. Cancer Chemother. Pharmacol. 32:1993;445-449.
23. Solem L.E., Heller L.J., Wallace K.B. Dose-dependent increase in sensitivity to calcium-induced mitochondrial dysfunction and cardiomyocyte cell injury by. J. Mol. Cell. Cardiol. 28:1996;1023-1032.
24. Miwa N., Kanaide H., Meno H., Nakamura M. Adriamycin and altered membrane function in hearts. Br. J. Exp. Pathol. 67:1986;747-755.
25. Pessah I.N., Durie E.L., Schiedt M.J., Zimany I. Anthraquinone-sensitized Ca release channel from rat cardiac sarcoplasmic reticulum: possible receptor-mediated mechanism of doxorubicin cardiomyopathy. Mol. Pharmacol. 37:1990;503-514.
26. Nohl H., Gille L., Staniek K. The exogenous NADH dehydrogenase of heart mitochondria is the key enzyme responsible for selective cardiotoxicity of anthracyclines. Z. Naturforsch.[C]. 53:1998;279-285.
27. Boucek R.J. Jr., Olson R.D., Brenner D.E., Ogunbunmi E.M., Inui M., Fleischer S. The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps: a correlative study of cardiac muscle with isolated membrane fractions. J. Biol. Chem. 262:1987;15851-15856.
28. Ito K., Yan X., Feng X., Manning W.J., Dillmann W.H., Lorell B.H. Transgenic expression of sarcoplasmic reticulum Ca(2+) atpase modifies the transition from hypertrophy to early heart failure. Circ. Res. 89:2001;422-429.
29. Avellanal M., Rodriguez P., Barrigon S. Protective effects of cyclopiazonic acid on ischemia-reperfusion injury in rabbit hearts. J. Cardiovasc. Pharmacol. 32:1998;845-851.
30. Meldrum D.R., Cleveland J.C. Jr., Mitchell M.B., Rowland R.T., Banerjee A., Harken A.H. Constructive priming of myocardium against ischemia-reperfusion injury. Shock. 6:1996;238-242.
31. Liu X., Chen Z., Chua C.C., Ma Y.S., Youngberg G.A., Hamdy R., Chua B.H. Melatonin as an effective protector against doxorubicin-induced cardiotoxicity. Am. J. Physiol. Heart Circ. Physiol. 283:2002;H254-H263.
32. Herman E.H., Ferrans V.J. Preclinical animal models of cardiac protection from anthracycline-induced cardiotoxicity. Semin. Oncol. 25(4 Suppl 10):1998;15-21.